Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH

Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH

Source: 
Endpoints
snippet: 

On Monday afternoon, though, the French biotech Inventiva announced that they had won breakthrough status, becoming — by their count — the first company to receive the designation for a NASH drug since Intercept did 5 years ago. It was enough to send the company’s stock up 6%, from $13.65 to $14.50 pre-market.